APSS

Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia

... are the details on each of these data presentations. At apss on June 10, 2009, Dr. Todd Swick will be presenting a poster entitled "Impa...ial of Sodium Oxybate" in the 10:15 am-12:15 pm poster session. At apss on June 11, 2009 at 9:00 am in Ballroom 6E, Dr. Swick will also deliver an ...

Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June

...ess, physical health and longevity, said Dr. Michael Vitiello, chair of the apss program committee. The information presented during SLEEP 2008 will help t... and the Sleep Research Society. In addition to organizing SLEEP 2008, the apss also publishes Sleep, a monthly peer-reviewed scientific journal. The S...

Greenway Medical Technologies Strengthens Industry Leadership With Participation in the IHE Connectathon and HIMSS Interoperability Showcase

...ice revenue and enhance improvements in patient care and overall population health while facilitating public health research and quality measures like apss and RFDs. To enhance the success and adoption of these two initiatives, Greenway is also promoting Cross-Enterprise Document Sharing (XDS.b), which ...

APSS in Medical Technology

Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia

...ere headache, nausea, dizziness, vomiting, diarrhea, anxiety, and sinusitis. Additional details on the data presented at the 2009 apss can be found at http://www.journalsleep.org/PDF/AbstractBook2009.pdf (abstract 0984, p.354). Development Plans Jazz Pharmaceuticals ha...

Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose

...ons of available therapies," said Dr. Roth, who participated in a June 2008 apss symposium convened to discuss the prevalence and consequences of nocturnal ...ew Approach for Patients with Middle of the Night Awakenings In a related apss poster presentation, investigators described a study in which they sought t...

Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting

... Minnesota. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company. Data presented at the apss meeting today includes the following: "Safety and Tolerability in Early Phase I Studies of NG2-73, a Novel GABA(A) Sleep Agent" NG2-73 is a GABA(A)...

Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia

...rofessional Sleep Societies (APSS) Annual Meeting. apss highlights show that insomnia is significantly und...care System and Labor Force. New data presented at apss demonstrates the significant impact insomnia has o... Medical Officer of Neurocrine Biosciences. apss Presentation Highlights: Study Demonstrates ...

Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo

... and staying asleep longer," said Tom Roth, Ph.D., Director of the Henry Ford Sleep Disorders and Research Center in Detroit, MI, presenter at today's apss session. "These subjective measures support data collected in the sleep lab and provide an important dimension for assessing the efficacy of VEC-162."...